COST EFFECTIVENESS OF VIBEGRON FOR THE TREATMENT OF OVERACTIVE BLADDER IN THE UNITED STATES

被引：0
|
作者：
Chen, J., V [1 ]
Klein, T. M. [1 ]
Mudd, P. [2 ]
机构：
[1] Med Decis Modeling Inc, Indianapolis, IN USA
[2] Urovant Sci, Durham, NC USA
来源：
VALUE IN HEALTH | 2021年 / 24卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PUK6
引用
收藏
页码：S235 / S235
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness of vibegron for the treatment of overactive bladder in the United States
    Chen, Jing Voon
    Klein, Timothy M.
    Nesheim, Jeffrey
    Mudd, Paul N., Jr.
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2022, 25 (01) : 1092 - 1100
  • [2] BUDGET IMPACT ANALYSIS OF VIBEGRON FOR THE TREATMENT OF OVERACTIVE BLADDER IN THE UNITED STATES
    Nesheim, J.
    Chen, J., V
    Gahn, J. C.
    Mudd, P.
    [J]. VALUE IN HEALTH, 2021, 24 : S234 - S235
  • [3] Evaluating vibegron for the treatment of overactive bladder
    Rechberger, Tomasz
    Wrobel, Andrzej
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2021, 22 (01) : 9 - 17
  • [4] COST OF OVERACTIVE BLADDER IN THE UNITED STATES
    Ganz, M. L.
    Smalarz, A. M.
    Anger, J. T.
    Krupski, T. L.
    Hu, J. C.
    Wittrup-Jensen, K. U.
    Pashos, C. L.
    [J]. VALUE IN HEALTH, 2008, 11 (06) : A652 - A652
  • [5] Vibegron for the treatment of overactive bladder: a comprehensive update
    Gleicher, Stephanie
    Sebesta, Elisabeth M.
    Reynolds, W. Stuart
    Dmochowski, Roger
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2022, 23 (13) : 1479 - 1484
  • [6] Re: Evaluating Vibegron for the Treatment of Overactive Bladder
    Wein, Alan J.
    [J]. JOURNAL OF UROLOGY, 2021, 206 (01): : 167 - 168
  • [7] Vibegron (Gemtesa) for Overactive Bladder
    不详
    [J]. MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2021, 63 (1623): : 67 - 69
  • [8] An Evaluation of the Efficacy and Safety of Vibegron in the Treatment of Overactive Bladder
    Frankel, Jeffrey
    Staskin, David
    Varano, Susann
    Kennelly, Michael J.
    Jankowich, Rachael A.
    Haag-Molkenteller, Cornelia
    [J]. THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2022, 18 : 171 - 182
  • [9] COST-EFFECTIVENESS ANALYSIS OF MIRABEGRON VERSUS TOLTERODINE EXTENDED RELEASE IN THE TREATMENT OF PATIENTS WITH OVERACTIVE BLADDER IN THE UNITED STATES
    Xie, J.
    Zhou, Z. Y.
    Bui, C. N.
    Yan, Y.
    De, G.
    Runken, M. C.
    Wu, E. Q.
    [J]. VALUE IN HEALTH, 2012, 15 (07) : A457 - A457
  • [10] COST-EFFECTIVENESS OF PHARMACOLOGIC TREATMENT OF OVERACTIVE BLADDER
    Malone, D. C.
    Armstrong, E. P.
    Bui, C.
    [J]. VALUE IN HEALTH, 2012, 15 (04) : A155 - A155
12345